X. He
Regend Therapeutics (China)(CN)South China University of Technology(CN)
Publications by Year
Research Areas
Glycosylation and Glycoproteins Research, Neuroblastoma Research and Treatments, Cancer Immunotherapy and Biomarkers, Glioma Diagnosis and Treatment, Kidney Stones and Urolithiasis Treatments
Most-Cited Works
- → Disialoganglioside GD2 in human neuroectodermal tumor cell lines and gliomas(1991)58 cited
- → GD3 expression by cultured human tumor cells of neuroectodermal origin(1989)26 cited
- → 2O Penpulimab, an IgG1 anti-PD-1 antibody with Fc-engineering to eliminate effector functions and with unique epitope and binding properties(2021)7 cited
- → Circulating glycoconjugates in CSF of meningioma patients(1990)6 cited
- → DISTRIBUTION OF GANGLIOSIDE GD3 IN CULTURED HUMAN TUMOR CELLS OF NEUROECTODERMAL ORIGIN AS DEFINED BY ANTI-GD3 MONOCLONAL ANTIBODIES(1989)1 cited
- → Clinical comparison of lateral supine position mini-percutaneous nephrolithotomy and anatrophic nephrolithotomy in the treatment of complete staghorn renal calculi(2024)
- → EXPRESSION OF GD2 BY TUMOR CELL LINES OF NEUROECTODERMAL ORIGIN AND HUMAN GLIOMAS AS DEFINED BY AN EPITOPE-DEFINED ANTI-GD2 MONOCLONAL ANTIBODY(1990)
- → Abstract 6062: A novel bi-specific antibody targeting CD39 and PD-L1 for enhanced cancer immunotherapy(2025)